{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T11:40:07Z","timestamp":1743075607750,"version":"3.40.3"},"reference-count":33,"publisher":"BMJ","issue":"e2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2024,7,31]]},"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Patients with life-limiting illnesses are at increased risk of mucosal bleeding. Usual management includes anticipatory planning and sedation, alongside anti-fibrinolytics, despite a lack of evidence for their use. Anti-fibrinolytic agents (tranexamic acid and aminocaproic acid) produce effective haemostasis in different clinical settings. Our aim was to synthesise the evidence for anti-fibrinolytic medication use in adult patients with life-limiting illnesses at risk of, or experiencing, mucosal bleeding.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched MEDLINE, Embase, CINAHL, Web of Science Conference Proceedings Citation Index, Cochrane Library databases and clinical trial registries (inception to January 2024) to identify studies investigating the use of anti-fibrinolytics in patients with life-limiting illnesses. Results were screened against a priori inclusion criteria, data ere extracted, and quality was appraised using a CASP (Critical Appraisal Skills Programme) checklist or BMJ risk of bias assessment. Data were analysed using narrative synthesis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Five studies meeting our search criteria (one cohort and four case series) were included. Data relating from 87 patients were used in narrative synthesis. Anti-fibrinolytic therapy was used for active mucosal bleeding in 37 patients, of whom 30 achieved total bleeding cessation. Fifty patients received prophylactic anti-fibrinolytics, of whom 32 experienced no bleeding events. Adverse events were reported in 3 of 87 patients (arterial thrombus, severe thrombocytopenia and stomach cramps). Mortality and quality of life were not reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Anti-fibrinolytics are generally well tolerated within this population and may prevent and reduce mucosal bleeding. Further high-quality research is suggested to investigate current practice and to compare anti-fibrinolytic with placebo in the management of bleeding in patients with life-limiting illnesses.<\/jats:p><\/jats:sec><jats:sec><jats:title>PROSPERO registration number<\/jats:title><jats:p>CRD42022325529.<\/jats:p><\/jats:sec>","DOI":"10.1136\/spcare-2024-005042","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T17:20:17Z","timestamp":1725038417000},"page":"e1663-e1670","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-fibrinolytics for mucosal bleeding in adults with life-limiting illnesses: a systematic review"],"prefix":"10.1136","volume":"14","author":[{"given":"Emma","family":"Hooson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Hargreaves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6308-1061","authenticated-orcid":false,"given":"Emily","family":"Holdsworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5717-1001","authenticated-orcid":false,"given":"Sarah","family":"Longwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Pullinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"key":"2025032703260712000_14.e2.e1663.1","unstructured":"Yorkshire palliative medicine guidelines group . Guidelines on the management of bleeding for palliative care patients with cancer. Leeds. Available: https:\/\/www.palliativedrugs.org\/download\/090331_Final_bleeding_guideline.pdf [Accessed 15 May 2024]."},{"key":"2025032703260712000_14.e2.e1663.2","doi-asserted-by":"crossref","unstructured":"Pereira J , Brodeur J . The management of bleeding in palliative care. In: Cherny N , ed. Oxford textbook of palliative medicine. Oxford Textbook(Oxford, 2015; online edn, Oxford Academic), Available: https:\/\/doi.org\/10.1093\/med\/9780199656097.003.0087 [accessed 15 May 2024].","DOI":"10.1093\/med\/9780199656097.003.0087"},{"key":"2025032703260712000_14.e2.e1663.3","doi-asserted-by":"crossref","unstructured":"Watson M , ed. Oxford handbook of palliative care. In: Oxford medical handbooks. 3rd edn. Oxford Academic, 2019. Available: https:\/\/doi.org\/10.1093\/med\/9780198745655.001.0001 [accessed 14 May 2024].","DOI":"10.1093\/med\/9780198745655.001.0001"},{"key":"2025032703260712000_14.e2.e1663.4","unstructured":"National Institute for Health and Care Excellence Clinical Knowledge Summaries (NICE CKS) . Palliative care - malignant skin ulcer. 2023. Available: https:\/\/www.nice.org.uk\/cks-uk-only#:~:text=Palliative%20care%20-%20malignant%20skin%20ulcer%3A%20Summary&text=Primary%20care%20managem [Accessed 28 May 2024]."},{"key":"2025032703260712000_14.e2.e1663.5","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13348"},{"key":"2025032703260712000_14.e2.e1663.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30638-4"},{"key":"2025032703260712000_14.e2.e1663.7","doi-asserted-by":"publisher","DOI":"10.3310\/hta17370"},{"key":"2025032703260712000_14.e2.e1663.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201171"},{"key":"2025032703260712000_14.e2.e1663.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31033-X"},{"key":"2025032703260712000_14.e2.e1663.10","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/S2352-3026(18)30215-1","article-title":"Prevalence, symptom burden, and natural history of deep vein thrombosis in people with advanced cancer in specialist palliative care units (HIDDen): a prospective longitudinal observational study","volume":"6","author":"White","year":"2019","journal-title":"Lancet Haematol"},{"key":"2025032703260712000_14.e2.e1663.11","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1016\/S0049-3848(20)30410-2","article-title":"Venous thromboembolism in palliative care patients: what do we know?","volume":"191","author":"Noble","year":"2020","journal-title":"Thromb Res"},{"key":"2025032703260712000_14.e2.e1663.12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.thromres.2018.12.028","article-title":"Thromboembolic disease in palliative and end-of-life care: a narrative review","volume":"175","author":"Chin-Yee","year":"2019","journal-title":"Thromb Res"},{"key":"2025032703260712000_14.e2.e1663.13","first-page":"182","article-title":"Tranexamic acid and thrombosis","volume":"22","year":"2013","journal-title":"Prescrire Int"},{"key":"2025032703260712000_14.e2.e1663.14","unstructured":"Health Improvement Scotland Right Decision Service . Scottish palliative care guidelines - bleeding from skin (including fungating tumours) and mucous membranes. Available: https:\/\/rightdecisions.scot.nhs.uk\/scottish-palliative-care-guidelines\/palliative-emergencies\/bleeding\/medication [Accessed 15 May 2024]."},{"key":"2025032703260712000_14.e2.e1663.15","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(20)30848-5","article-title":"Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial","volume":"395","year":"2020","journal-title":"The Lancet"},{"key":"2025032703260712000_14.e2.e1663.16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"2025032703260712000_14.e2.e1663.17","unstructured":"Team TE . EndNote. 20th edn. Philadelphia, PA: Clarivate, 2013."},{"key":"2025032703260712000_14.e2.e1663.18","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4"},{"key":"2025032703260712000_14.e2.e1663.19","unstructured":"Critical Appraisal Skills Programme . CASP cohort study checklist. Oxford. Available: https:\/\/casp-uk.net\/checklists\/casp-cohort-studies-checklist-fillable.pdf [Accessed 15 May 2024]."},{"key":"2025032703260712000_14.e2.e1663.20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2017-110853"},{"key":"2025032703260712000_14.e2.e1663.21","unstructured":"Centre for Reviews and Dissemination . Systematic review - crd\u2019s guidance for undertaking reviews in health care. University of York. Available: https:\/\/www.york.ac.uk\/media\/crd\/Systematic_Reviews.pdf [Accessed 15 May 2024]."},{"key":"2025032703260712000_14.e2.e1663.22","unstructured":"Popay J , Roberts H , Sowden AJ , et al . Guidance on the conduct of narrative synthesis in systematic reviews. a product from the esrc methods programme. Lancaster. Available: https:\/\/www.lancaster.ac.uk\/media\/lancaster-university\/content-assets\/documents\/fhm\/dhr\/chir\/NSsynthesisguidanceVersion1-April2006.pdf [Accessed 15 May 2024]."},{"key":"2025032703260712000_14.e2.e1663.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2021-003427"},{"key":"2025032703260712000_14.e2.e1663.24","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/cncr.28253","article-title":"Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies","volume":"119","author":"Antun","year":"2013","journal-title":"Cancer"},{"key":"2025032703260712000_14.e2.e1663.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(96)00202-3"},{"key":"2025032703260712000_14.e2.e1663.26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/0825859717731701","article-title":"Bleeding Control in Palliative Care Patients With the Help of Tranexamic Acid","volume":"32","author":"Geist","year":"2017","journal-title":"J Palliat Care"},{"key":"2025032703260712000_14.e2.e1663.27","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4103\/IJPC.IJPC_48_20","article-title":"High-dose Continuous Infusion of Tranexamic Acid for Controlling Life-threatening Bleed in Advanced Cancer Patients","volume":"27","author":"Atreya","year":"2021","journal-title":"Indian J Palliat Care"},{"key":"2025032703260712000_14.e2.e1663.28","unstructured":"Oxford Centre for Evidence Based Medicine . OCEBM levels of evidence working group. The oxford levels of evidence 2,Oxford. Available: https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence [Accessed 15 May 2024]."},{"key":"2025032703260712000_14.e2.e1663.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00822.x"},{"key":"2025032703260712000_14.e2.e1663.30","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2021.0884","article-title":"Association of Intravenous Tranexamic Acid With Thromboembolic Events and Mortality: a Systematic Review, Meta-analysis, and Meta-regression","volume":"156","author":"Taeuber","year":"2021","journal-title":"JAMA Surg"},{"key":"2025032703260712000_14.e2.e1663.31","unstructured":"Cochrane Collaboration . Cochrane handbook for systematic reviews of interventions version 5.1.0. London. Available: https:\/\/handbook-5-1.cochrane.org [Accessed 15 May 2024]."},{"key":"2025032703260712000_14.e2.e1663.32","unstructured":"CASP . Different types of bias in research- casp. CASP - Critical Appraisal Skills Programme; 2024. Available: https:\/\/casp-uk.net\/news\/different-types-of-research-bias [Accessed 12 Jun 2024]."},{"key":"2025032703260712000_14.e2.e1663.33","unstructured":"Charlesworth S , ed. Palliative Care Formulary. 7th edn. Pharmaceutical Press, 2020."}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/spcare-2024-005042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T11:04:16Z","timestamp":1743073456000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/spcare-2024-005042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":33,"journal-issue":{"issue":"e2","published-online":{"date-parts":[[2024,11,15]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1136\/spcare-2024-005042"],"URL":"https:\/\/doi.org\/10.1136\/spcare-2024-005042","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"type":"print","value":"2045-435X"},{"type":"electronic","value":"2045-4368"}],"subject":[],"published":{"date-parts":[[2024,8,30]]}}}